Radiology Business

JULY 23, 2024

The Melbourne, Australia-based radiopharmaceutical firm plans to use the proceeds to accelerate development of products in its theranostics portfolio

Pharmaceutical 292

Pharmaceutical Radiopharmaceuticals Imaging IT 292

AuntMinnie

MAY 1, 2024

Food and Drug Administration (FDA) has approved Novartis' Lutathera (lutetium-177 [Lu-177]) DOTATATE radiopharmaceutical for treatment of pediatric patients who are 12 years old and older with somatostatin receptor (SSTR)-positive gastroentropancreatic neuroendocrine tumors (GEP-NETs).

Radiopharmaceuticals 240

Radiopharmaceuticals Pharmaceutical Radiology 240

AuntMinnie

JULY 12, 2024

Reshaping the hospital's nuclear medicine and radiopharmaceutical strategy toward theranostics involves intensive and inclusive planning, Beyder explained at SNMMI. Theranostics offers hospital radiology departments the opportunity to keep more reimbursement dollars in the department, Beyder explained.

Nuclear Medicine 264

Nuclear Medicine Radiation Oncology Radiopharmaceuticals Radiation 264

AuntMinnie

FEBRUARY 16, 2024

Fusion Pharmaceuticals announced a patent dispute settlement and new licensing agreement with Heidelberg University and Euratom for exclusive, worldwide rights to their existing patent for FPI-2265, an actinium-225-based targeted radiotherapy for the treatment of prostate-specific membrane antigen (PSMA)-expressing cancers.

Pharmaceutical 100

Pharmaceutical Radiopharmaceuticals Medical IT 100

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine 264

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology 264

AuntMinnie

JUNE 10, 2024

Evans, a professor in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco, was recognized for his work in biomarker discovery and radiopharmaceutical development. He will be honored at the SNMMI's annual meeting in Toronto.

Nuclear Medicine 100

Nuclear Medicine Radiopharmaceuticals Pharmaceutical Clinic 100

Imaging Technology

JULY 9, 2024

Marco Campione brings more than 25 years of experience from GE HealthCare, where he most recently served as Executive Director and Global Head of Contrast Media, General Manager Pharmaceutical Diagnostics North America and President GE HealthCare Inc., Campione also joins the Blue Earth Diagnostics Ltd. Bracco Imaging S.p.A.,

Diagnostic 105

Diagnostic Radiopharmaceuticals Nuclear Medicine Magnetic Resonance Imaging 105